Wedbush analyst Liana Moussatos reiterated a Buy rating on Intercept Pharma (ICPT) today and set a price target of $74.00. The company’s shares closed last Thursday at $16.75, close to its 52-week low of $13.88.
According to TipRanks.com, Moussatos is a 3-star analyst with an average return of 5.5% and a 41.1% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Eiger Biopharmaceuticals, and BioMarin Pharmaceutical.
Intercept Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $33.88, representing a 97.9% upside. In a report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $82.00 price target.
See today’s analyst top recommended stocks >>
Based on Intercept Pharma’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $81.66 million and GAAP net loss of $40.42 million. In comparison, last year the company earned revenue of $72.65 million and had a GAAP net loss of $92.98 million.
Based on the recent corporate insider activity of 67 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ICPT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.
